Emmaus Life Sciences Inc (EMMA) fair value: what the stock is really worth
As of Sep 29, 2026: fair value of Emmaus Life Sciences Inc $0.04, price $0.07, upside -46.0%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Emmaus Life Sciences Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range $0.0001 – $2.15 · the $0.0655 price screens above the $0.0354 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Emmaus Life Sciences in your weekly email
Every Wednesday you see whether Emmaus Life Sciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
Show more
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Stock analysis
Emmaus Life Sciences Inc (EMMA) currently trades at $0.0655, while our model-based Fair Value estimate is $0.0354, 46.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $0.0500 per share, and 0 of the 5 models we run sit above the $0.0655 price.
Bear case: the Earnings-Based group reads lowest at $0.0200, and 5 of the 5 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Emmaus Life Sciences Inc reported revenue of $12.5M in FY2025 versus $20.6M in FY2021, a compound −11.8%/yr. Reported net income was −$7.5M in FY2025.
Key figures
Market cap $674K · P/S ratio 0.05 · EPS (TTM) $−0.1300 · Net margin −60.2% · Return on assets (EBIT) −4.3% · Revenue (TTM) $12.5M · Revenue growth (YoY) +17.0% · EPS growth (YoY) +22.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 21% below its 52-week high and 680% above its 52-week low.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −46%, EMMA screens richer than that median.
Fair Value models
Bear $0.0354Fair Value $0.0354Bull $0.0354
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−25.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.7%
Start year 2020 (pandemic). Over 10 years: +62.0% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+28.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.2% (2020) → 1.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Emmaus Life Sciences Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 576 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score24 · Bottom 25%
Fair Value upside−46.0% · Above median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets0.6% · Above median
Net margin (TTM)−60.2% · Bottom 25%
Operating margin (TTM)0.0% · Above median
Growth and dividend
Revenue growth17.0% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)85· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Emmaus Life Sciences Inc Fair Value". https://www.fairvalue-calculator.com/stock/EMMA
Frequently asked questions
Is Emmaus Life Sciences Inc (EMMA) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0354 versus a price of $0.0655, about −46% upside (overvalued).
What is the fair value of EMMA?
Our model-based fair value for Emmaus Life Sciences Inc is $0.0354 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0655.
What is the quality score of EMMA?
Emmaus Life Sciences Inc has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Emmaus Life Sciences Inc (EMMA)?
Our model-based price target is the fair value of $0.0354 (as of Sep 27, 2026) from 5 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Emmaus Life Sciences Inc stock forecast for 2026?
Our models put fair value at $0.0354, about −46% upside versus a price of $0.0655 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Emmaus Life Sciences Inc (EMMA)?
Emmaus Life Sciences Inc reported trailing-twelve-month revenue of about $12.5M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Emmaus Life Sciences Inc (EMMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Emmaus Life Sciences Inc it is $0.0354 per share (as of Sep 27, 2026), against a price of $0.0655. It is the blended result of 5 valuation models (cash flow, earnings, asset, dividend).
Is Emmaus Life Sciences Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, EMMA trades above its calculated fair value: price $0.0655, fair value $0.0354, a gap of about −46% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of EMMA?
No. The price is what the market pays today ($0.0655); the fair value is what the company's own numbers justify ($0.0354). For Emmaus Life Sciences Inc the two are $0.0301 per share apart. That gap is exactly why we show both numbers side by side.
How much is Emmaus Life Sciences Inc worth?
The market values Emmaus Life Sciences Inc at about $674K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0655; our models calculate a fair value of $0.0354 per share.
How solid is the balance sheet of Emmaus Life Sciences Inc (EMMA)?
Balance-sheet figures for Emmaus Life Sciences Inc (as of Sep 27, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is EMMA from its 52-week high?
Emmaus Life Sciences Inc trades at $0.0655, about 21% below its 52-week high of $0.0830 and 680% above the low of $0.0084 (as of Sep 29, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0354 is for.
Which stocks are comparable to Emmaus Life Sciences Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Emmaus Life Sciences Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0655, calculated fair value $0.0354 (−46%), Quality Score 25/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of EMMA calculated?
We run Emmaus Life Sciences Inc through 5 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0354, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Emmaus Life Sciences Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Emmaus Life Sciences Inc (EMMA)?
The closing price on Sep 29, 2026 was $0.0655. Our model-based fair value is $0.0354, about −46% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Emmaus Life Sciences Inc right now?
The price sits above even our optimistic bull case ($0.0354). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Emmaus Life Sciences Inc
How large is the market capitalisation of Emmaus Life Sciences Inc (EMMA)?
The market capitalisation of Emmaus Life Sciences Inc is $674K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Emmaus Life Sciences Inc (EMMA)?
The price-to-sales ratio of Emmaus Life Sciences Inc is 0.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Emmaus Life Sciences Inc (EMMA)?
Earnings per share at Emmaus Life Sciences Inc are $−0.1300. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Emmaus Life Sciences Inc (EMMA)?
The net margin of Emmaus Life Sciences Inc is −60.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Emmaus Life Sciences Inc (EMMA)?
On an EBIT basis the return on assets of Emmaus Life Sciences Inc is −4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Emmaus Life Sciences Inc (EMMA)?
Revenue at Emmaus Life Sciences Inc is growing +17.0% versus a year earlier (3y avg −12.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Emmaus Life Sciences Inc (EMMA)?
Earnings per share at Emmaus Life Sciences Inc are growing +22.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Emmaus Life Sciences Inc (EMMA) generate?
The free cash flow of Emmaus Life Sciences Inc is −$12.0K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Emmaus Life Sciences Inc (EMMA) carry?
The net debt of Emmaus Life Sciences Inc is $28.7M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Emmaus Life Sciences Inc in the live analysis
One click puts Emmaus Life Sciences Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026